产品
编 号：F453904
分子式：C11H17N3O
分子量：207.27
分子式：C11H17N3O
分子量：207.27
产品类型
规格
价格
是否有货
500μg
询价
询价
结构图
CAS No: 76896-80-5
产品详情
生物活性：
Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C is found to be highly effective against rotavirus replication.
体内研究：
Triacsin C (8-15 mg/kg/d; p.o.; 1 week) shows anticryptosporidial efficacy and improves Cryptosporidium parvum infection by targeting parasite fatty acyl-coenzyme A synthetases.Triacsin C (10 mg/kg/d; p.o.; 2 months) exhibits anti-atherosclerotic activity in aortic atherosclerosis LDLR-/- mice.Animal Model:Cryptosporidium-infected interleukin knockout mice
Dosage:8-15 mg/kg/d
Administration:Oral gavage; 1 week
Result:Reduced parasite oocyst production up to 88.1% with no apparent toxicity.
Animal Model:Low-density lipoprotein receptor-knockout (LDLR-/-) mice (C57BL/6 background)
Dosage:10 mg/kg/d
Administration:Oral gavage; 2 months
Result:Increased plasma TG, plasma cholesterol, plasma free fatty acid, and plasma glucose concentration.Improved the growth of aortic atherosclerosis mice, increased the body weight of mince.
体外研究：
Triacsin C (0-16 μM; 41 h) inhibits parasite fatty acyl-coenzyme A synthetases, and reduces CpACS1 and CpACS2 enzymes activities with IC50s of 3.70 μM and 2.32 μM, respectively, with Ki values of 595 nM and 106 nM, respectively.Triacsin C (0-16 μM; 41 h) shows anti-parasitic and inhibits Cryptosporidium parvum with an IC50 value of 136 nM.Triacsin C (0, 0.25, 0.5 μM; 30 min) has no effect on parasite invasion.
Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity. Triacsin C is found to be highly effective against rotavirus replication.
体内研究：
Triacsin C (8-15 mg/kg/d; p.o.; 1 week) shows anticryptosporidial efficacy and improves Cryptosporidium parvum infection by targeting parasite fatty acyl-coenzyme A synthetases.Triacsin C (10 mg/kg/d; p.o.; 2 months) exhibits anti-atherosclerotic activity in aortic atherosclerosis LDLR-/- mice.Animal Model:Cryptosporidium-infected interleukin knockout mice
Dosage:8-15 mg/kg/d
Administration:Oral gavage; 1 week
Result:Reduced parasite oocyst production up to 88.1% with no apparent toxicity.
Animal Model:Low-density lipoprotein receptor-knockout (LDLR-/-) mice (C57BL/6 background)
Dosage:10 mg/kg/d
Administration:Oral gavage; 2 months
Result:Increased plasma TG, plasma cholesterol, plasma free fatty acid, and plasma glucose concentration.Improved the growth of aortic atherosclerosis mice, increased the body weight of mince.
体外研究：
Triacsin C (0-16 μM; 41 h) inhibits parasite fatty acyl-coenzyme A synthetases, and reduces CpACS1 and CpACS2 enzymes activities with IC50s of 3.70 μM and 2.32 μM, respectively, with Ki values of 595 nM and 106 nM, respectively.Triacsin C (0-16 μM; 41 h) shows anti-parasitic and inhibits Cryptosporidium parvum with an IC50 value of 136 nM.Triacsin C (0, 0.25, 0.5 μM; 30 min) has no effect on parasite invasion.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备